Regenerative and targeted therapies increase the need to accurately identify rare diseases, and increased specificity in diagnosis codes of the ICD-10 could help.

Since the start of the COVID-19 pandemic, influenza positivity rates have remained at the lowest levels documented in modern history.

Expanding the utility and consistency of existing claims-coding processes may offer a low-effort, high-value return for health economics and outcomes research.